(UroToday.com) At the 2021 American Society of Clinical Oncology Genitourinary Cancers annual meeting (ASCO GU), Dr. Daniel George and colleagues presented a subgroup analysis assessing the impact of concomitant prostate cancer therapy on the safety and efficacy of the oral GnRH receptor antagonist relugolix versus leuprolide in men with advanced prostate cancer. In the phase 3 HERO study,1 relugolix demonstrated suppression of testosterone to castrate levels in 96.7% of patients, which was superior to leuprolide, with a 54% lower risk of major adverse cardiovascular events relative to leuprolide. Relugolix is a first-in-class Federal Drug Administration (FDA) approved, oral, highly selective, GnRH receptor antagonist that is given once daily with an effective half-life of 25 hours. To characterize the impact of concomitant prostate cancer treatments with the use of relugolix in advanced prostate cancer from the HERO study, a subgroup analysis for patients receiving various therapies was undertaken. The HERO study allowed concomitant treatments in patients who developed disease progression within the 48-week treatment period.